TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 7-day Point Prevalence Abstinence at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day Point Prevalence Abstinence at Week 52
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day Point Prevalence Abstinence at Follow-up Week 64
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day Point Prevalence Abstinence at Follow-up Week 104
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Curve (AUC) for glycemic and insulinemic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of patients unable to optimize AV delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Collapsibility index of the inferior vena cava
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of enrolled patients who submit an online questionnaire
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of total attended visits during the study period at which a questionnaire was completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of undiagnosed stage 3 chronic kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to CKD diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent Change From Baseline in Serum TTR Concentration at Week 65
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of the biomarkers in predicting the pathological diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic and Liver Triglyceride (Fat) Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and Severity of Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in baseline language skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell Fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications during hospital stay
Endpoint domain: Adverse events/effects
Primary endpoint: Bile drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acceptability of Ready-to-Use Complementary Food supplement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total exercise duration at a constant submaximal load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of 8-oxoguanosine (nmol/24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of 8-oxodeoxoguanosine (nmol/24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained improvement in free-living activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the Genitourinary Pain Index (GUPI) 2 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Genitourinary Pain Index (GUPI) 5 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of utilization of nutritional interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peak analgesic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Increase in High-Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of RO4995819
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of score in Zarit Burden Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of score in WHO-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of score in Meaning in caregiving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Breath Alcohol Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from all-cause peri-operative death
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from index limb amputation
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from index limb re-intervention
Endpoint domain: Mortality/survival
Primary endpoint: Intradialytic desaturation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment of cognitive and executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: occurrence of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: midcycle endometrial thickness (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Response rate evaluated by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ctDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pediatric Sleep Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of patients achieving tacrolimus concentration >=10 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ADHD and oppositional behavior measured by IOWA Connors Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental Depressive Symptoms using Beck Depression Inventory-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-operative stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantitative magnetic susceptibility in the human brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MADRS Score - Overall Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of students reporting being enrolled and regularly attending school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Renal Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: abdominal and peri-hepatic adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achieved Flap Thickness at Day 1 Postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Upper limb muscle activation envelopes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematics during active movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in weekly PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: First occurrence of fatal or non-fatal acute MI, unstable angina, stroke, congestive heart failure, or revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Incident ARDS (Adult Respiratory Distress Syndrome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incident hypoxic respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response rate based on the improvement of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximally Tolerable Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for vitamin D delivery system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wound aspect - major complication
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visibility of OCTA key anatomical vascular structures quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of vascular abnormalities on OCTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the Number of Seizure Days With Absence Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the Number of Seizure Days With Myoclonic Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful outcome at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Partial Responders by Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical and pathological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CVD risk level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunotherapy adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year recurrence-free survival (RFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Hip function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve over 24 hours (AUC 0 to 24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 or higher signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in plasma renin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Seattle Angina Questionnaire (SAQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to composite endpoint of >=50% SCr increase from baseline or ESRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of AL amyloid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of Sunitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of Sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Triglycerides profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Developed Clinically-Apparent Rheumatoid Arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Electromagnetic interference
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve from time zero to 24 hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve from time zero to infinite (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction to intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-yrs progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: proportion of patients experiencing grade 3 or greater extra-hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Usability of the system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with no more tumor in their body
Endpoint domain: Mortality/survival
Primary endpoint: Brachial artery flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rating of Perceived Exertion (RPE)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rates of Hepatic Mitochondrial Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in estimated glomerular filtration rate (eGFR) at 5 years follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in the rate of eGFR change during 5 years follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in change in urine albumin excretion during 5 years follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite measure of TRSAE, mis- and altered diagnosis, and non-compliance
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of rHMPV-SHs infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rHMPV-SHs shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency and severity of respiratory illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum fundamental frequency of the voice range profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BUN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Uric Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Middle Cranial Fossa Dura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Photoallergic skin reactions (erythema and edema scoring)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of contrast media induced translocational hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Electrolyte and fluid balance outcomes
Primary endpoint: Global behavior observation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of peak inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean plaque lipid composition in carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-prandial SMA flows changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classes of vaginal flora before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classes of vaginal flora 6 weeks after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Quit Attempt
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Peak core body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of information regarding fertility preservation (FP)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Eyes With Immunologic Graft Rejection Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of JNJ-42165279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentrations of JNJ-42165279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations in cerebrospinal fluid of JNJ-42165279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of abnormal glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in ozone induced efferocytosis of lung macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ozone induced phagocytosis of lung macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Change or Decision That Heart Failure Therapy is Optimal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of CardioRenal Syndrome type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sum of the Cooling Scale For Rohto (r) Hydra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fibrosis evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in length-for-age Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Urinary Tract Infections (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of any hypoglycaemic event
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour blood pressure profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Plaque Index Score for Long-Term Care (PI-LTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change in Gingival Index Score for Long-Term Care (GI-LTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change in Denture Plaque Index Score (DPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change in Dyspnea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pain assessed by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of respiratory exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective Clinical Tumor Regression Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Port Failure Within 12 Months of Port Insertion
Endpoint domain: Adverse events/effects
Primary endpoint: number of hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Penetration-Aspiration Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Swallowing outcomes
Primary endpoint: Rate of MMR at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary artery and systemic endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Ki67 proliferative index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence and severity of local and systemic adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: P. falciparum blood stage infection defined as detection of P. falciparum parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Yale Brown Obsessive Compulsive Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CPAP adherence
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Agreement of Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: pathological response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL or +/- 5to15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Burnout (Teacher)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hyperglycemia control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes